Rakovina appoints Dr. Ranjit Bindra to scientific board

Rakovina Therapeutics Inc. has appointed Dr. Ranjit Bindra to its Scientific Advisory Board, according to a press release. Dr. Bindra, who serves as the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at Yale School of Medicine, has a strong research background with his laboratory discovering vulnerabilities in IDH1/2-mutant cancers to PARP inhibition, with findings published in prestigious scientific journals.

Rakovina Therapeutics, a biopharmaceutical company focused on developing cancer treatments using AI platforms, also received a tax refund from the Canada Revenue Agency, which will support its pipeline development.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.